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Abstract
Background: Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in
Indonesia before the initial launch of artemisinin combination therapy in 2004. A study to evaluate efficacies of
chloroquine against P. falciparum and P. vivax was undertaken at Lampung in southern Sumatra, western Indonesia
in 2002.
Methods: Patients infected by P. falciparum or P. vivax were treated with 25 mg/kg chloroquine base in three daily
doses over 48 hr. Finger prick blood was collected on Days 0, 2, 3, 7, 14, 21 and 28 after starting drug
administration. Whole blood chloroquine and its desethyl metabolite were measured on Days-0, -3 and -28, or on
the day of recurrent parasitaemia.
Results: 42 patients infected by P. falciparum were enrolled, and 38 fullfilled criteria for per protocol analysis. Only
six of 38 (16%) showed a response consistent with senstivity to chloroquine. 25 of 32 failures were confirmed
resistant by demonstrating chloroquine levels on day of recurrence exceeding the minimally effective
concentration (200 ng/mL whole blood). The 28-day cumulative incidence of resistance in P. falciparum was 68%
(95% CI: 0.5260 - 0.8306). Thirty one patients infected by P. vivax were enrolled, and 23 were evaluable for per
protocol analysis. 15 out of 23 (65%) subjects had persistent or recurrent parasitaemia. Measurement of chloroquine
levels confirmed all treatment failures prior to Day-15 as resistant. Beyond Day-15, 4 of 7 recurrences also had drug
levels above 100 ng/mL and were classified as resistant. The 28-day cumulative incidence of chloroquine resistance
in P. vivax was 43% (95% CI: 0.2715 - 0.6384).
Conclusion: These findings confirm persistantly high levels of resistance to chloroquine by P. falciparum in
southern Sumatra, and suggest that high-grade and frequent resistance to chloroquine by P. vivax may be
spreading westward in the Indonesia archipelago.
Background
Plasmodium falciparum and Plasmodium vivax each
cause an estimated one to two million cases of malaria
in Indonesia each year (SEARO). In 2004, the Ministry
Health of Indonesia abandoned chloroquine as first-line
treatment for P. falciparum and adopted artemisinin-
based combination therapy (ACT). Evidence of high
levels of chloroquine resistance by P. falciparum from
various areas of Indonesia drove this decision [1-7].
In contrast, high levels of chloroquine-resistant P.
vivax were reported only in hyper- to holoendemic
West Papua in the eastern part of Indonesia [6,8-10].
Even though evidence of this problem first appeared
nearly 20 years ago, chloroquine remained the front-line
therapy for vivax malaria. However, in 2007 the Ministry
of Health adopted ACT for vivax malaria in some parts
of West Papua in far eastern Indonesia. Evidence from
the western islands of Indonesia between 1992 until
1998, revealed relatively low risk (approx. 10%) of chlor-
oquine- resistant P. vivax [3,11-15]. Nonetheless, in
2008 national treatment policy was changed to apply
artesunate-amodiaquine as first-line therapy for vivax
malaria throughout Indonesia. However, that policy
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any medium, provided the original work is properly cited.applies only to confirmed vivax malaria, and cases diag-
nosed clinically still receive chloroquine or sulphadox-
ine/pyrimethamine as first-line therapy. Moreover,
widespread over-the-counter trade in chloroquine may
persist even longer. Thus, although this study was
undertaken prior to recent changes in malaria therapy




The study was conducted from June to September 2002
at Hanura Health Center in Lampung Province, southern
Sumatra. This health center covers a population resident
between 105° - 106° eastern longitude and 5° - 6° south-
ern latitude at the southern-most tip of Sumatra island.
Shrimp farming represented a major economic activity
and the ponds used in this industry, when neglected and
overgrown with algal mats, created breeding sites for
Anopheles sundaicus, an efficient and important malaria
vector in the region [16]. The rainy season in southern
Sumatra occurs from September until April, whereas the
rest of the year is relatively dry. Pribadi et al first
reported chloroquine-resistant P. falciparum from this
area in 1981 [2]. The health center was nonetheless using
chloroquine for first-line treatment of both falciparum
and vivax malaria at the time of this study.
Study subjects
A protocol detailing the work reported here was
reviewed and approved by the Ethics Committee of the
Faculty of Medicine, University of Indonesia. Patients
with fever or history of fever in the last 48 hours were
screened for mono- infection by P. falciparum or P.
vivax based on microscopic examination of Giemsa-
stained thick blood films. Inclusion criteria for either
infection was age ≥ 1 year, parasite count ≥ 1,000 asex-
ual parasites/μL blood and patients willing to sign
informed consent. The exclusion criteria were mixed
infection of plasmodia, pregnancy (HCG urine test),
complicated or severe malaria, or history of drug aller-
gies. Qualified patients provided informed consent and
were enrolled in the study.
The total dose of chloroquine was 25 mg base/kg body
weight over 48 hr (Day-0 & Day-1: 10 mg/kb and Day-2:
5 mg/kg). All doses were directly observed by a member
of the research team. If subjects vomited within the first
30 min after drug administration, the treatment was
repeated. If subjects vomited a second time they were
withdrawn from the study. A qualitative check on chloro-
quine consumption prior to visiting the health center was
done by Dill-Glazko urine test [17], but test outcome was
not a criterion for excluding patients from enrollment.
Subjects were asked to come back to the health center
on Day-1, -2, -3, -7, -14, -21, and -28, or at any time
they had fever. At each visit, except on Day-1, blood
was collected for microscopic examination for parasites,
as well as for measuring chloroquine level (100 μL dried
on Whatman #1 filter paper). Axillary temperature was
measured at each visit.
Treatment response
Treatment outcomes for P. falciparum were classified as
early treatment failure (ETF), late treatment failures
(LTF) and adequate clinical and parasitological
responses (ACPR) based on the WHO protocol [18]. In
brief, the criteria for ETF is parasitaemia on Day-3 with
axilary temperature ≥ 3 7 . 5 ° Co rd e n s i t yo fp a r a s i t a e m i a
on Day-2 is higher than Day-0 (≥ 75%) or density of
parasitaemia on Day-3 is ≥ 25% of Day-0 or clinical con-
dition of subjects becomes severe on Day-1, Day-2 or
Day-3 with positive parasitaemia. Patients were categor-
ized as LTF if between Day-4 and Day-28 parasitaemia
reappeared with an axillary temperature ≥ 37.5°C or
when parasitaemia recurred on Day-7, -14, -21 and -28
with axillary temperature < 37.5°C or subjects suffers
from severe condition with positive parasitaemia
between Day-4 until Day-28. Patients were classified
having ACPR if within 28 days follow up did not show
any signs of ETF or LTF.
Gauging and classifying the treatment response by P.
vivax was as applied elsewhere [19,20]. In brief, direct
treatment failures occurred if parasitaemia ≥ 25% Day-0
persisted to Day-3. Early treatment failure occurred if
parasitaemia at any level persisted until Day-4. A recur-
rence failure occurred if parasitaemia became subpatent
but reappeared between Day-5 and Day-28 after initiat-
ing treatment, and appeared with >100 ng chloroquine
and its major metabolite, desethyl-chloroquine (CQ
+DCQ) per mL whole blood [21]. Infections were classi-
fied as sensitive to chloroquine if parasitaemia was not
detectable by Day-3 and no recurrent parasitaemia
occurred up to Day-28.
Subjects were withdrawn from the study if they failed
to appear on scheduled follow-up visits, if they showed
intercurrent parasitaemia by another species of Plasmo-
dium, or if they had a recurrent parasitaemia by the
same species but with chloroquine levels below the
minimally effective concentration for that species (< 200
ng/mL or < 100 ng/mL for P. falciparum and P. vivax,
respectively).
Alternative treament with quinine (3 × 10 mg/kg bw
for 7 days) was offered to subjects having recurrent
parasitaemia. Plasmodium vivax infected patients were
also treated with primaquine (0.25 mg/kg per day × 14
d) at the end of follow up period or together with
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alternative therapies was not monitored.
Chloroquine levels
Chloroquine measurements were done with the assis-
tance of the U.S. Naval Medical Research Unit #2 in
Jakarta, Indonesia using their high performance liquid
chromatorgraphy (HPLC) instruments [22]. Whole
blood total chloroquine levels consisted of the sum of
CQ and DCQ, and was quantified on Day-0 (before
treatment), Day-3, Day-28 or on the day of recurrent
parasitaemia.
Statistical analyses
Data were double-entered into an ExcellTM database,
corrected, locked and entered into an SPSS version 16.0
for uni- and bi-variate analysis applying p ≤ 0.05 as the
limit of statistical significance. The cumulative risk of
treatment failure was estimated using the life table
method as described elsewhere [8], and 95% confidence
intervals were calculated with Stata software
Results
Screening patients
3,154 patients came to the health center between June
and September 2002, and 676 (21%) were screened for
malaria by microscopic examination of Giemsa-stained
blood films, of which 392 (58%) were found to be para-
sitaemic. These were P. falciparum (53% = 207/392), P.
vivax (43% = 168/392) and mixed infection of P. falci-
parum and P. vivax (4% = 17/392). Confirmed malaria
thus accounted for approximately 10% of patients seek-
ing medical attention at this health center.
Only 82 (39%) of 207 P. falciparum-infected patients
fullfilled the inclusion criteria. 123 had parasite counts
of less than 1,000/μL blood, one had a positive preg-
nancy test and another declined informed consent. 42 of
the eligible subject were randomized to this study and
received chloroquine therapy. The remaining 40 were
randomized to another protocol with sulphadoxine-pyri-
methamine, and will be reported separately. Among the
patients with P. vivax, only 31 of 137 (23%) had >1,000
asexual forms/μL, and all of these were enrolled in the
current study.
Demographic, clinical and parasitological characteristics
The sex ratio in both groups (P. falciparum and P.
vivax) was comparable (Table 1). The age of P. vivax-
infected subjects was not distinct from P. falciparum-
infected subjects. On the day of enrolment, 62% and
48% of P. falciparum and P. vivax subjects were febrile,
respectively. The geometric mean of parasite density
was higher in P. falciparum (8,759/μL) than P. vivax
(5,468/μL) subjects (Table 1). In both groups about one
quarter of subjects had positive Dill-Glazko urine tests
for chloroquine prior to supervised treatment.
Whole blood chloroquine levels
33 of 42 enrolled subjects infected by P. falciparum had
chloroquine levels measured. On the day of enrollment,
15 of the 33 subjects (46%) had chloroquine in blood
b e t w e e n6 7t o2 6 7n g / m L( 3o ft h e s ew e r ea b o v et h e
minimally effective concentration of 200 ng/mL). There
was no correlation between chloroquine level on Day-0
and Day-3 (Pearson correlation: r = 0.014, p value =
0.937). Furthermore, neither CQ+DCQ level on Day-0
nor density of parasitaemia on Day-0 correlated with
treatment failure (Fisher exact test: CQ Day-0: p value =
0.686, OR = 1.417, 95% CI = 0.259 - 7.763; Parasite den-
sity Day-0: p value = 1.000, OR = 1.000, 95% CI = 0.175
-5.710).
Chloroquine blood levels were measured before super-
vised treatment in 23 of the 31 P. vivax-infected sub-
jects, and 14 (65%) had chloroquine levels between 92
ng/mL to 392 ng/mL, all of these had CQ + DCQ above
minimally inhibitory concentration of ≥ 100 ng/mL
except one (92 ng/mL). There was no correlation
between CQ+DCQ level on Day-0 and Day-3 (Pearson
correlation: r = 0.007, p value = 0.974). Neither CQ
+DCQ level on Day-0 (Fisher exact: p value = 0.400, OR
= 2.625, 95% CI = 0.395 - 17.458) nor density of parasi-
taemia on Day-0 (Fisher exact: p value = 0.667, OR =
1.905, 95% CI = 0.330 - 11.009) were associated with
treatment failure.
Table 1 Demographic & clinical characteristics of subjects
Characteristic P. falciparum P. vivax
Number of subjects 42 31
Age (years)(median) (inter quartile range) 12 (7 - 17) 12.8 (1 - 60)
Male (percentage) 18 (43%) 14 (45%)
Body temperature on Day-0 (°C)(mean)(range) 37.8 (35.2 - 39.8) 37.6 (35.3 - 39.9)
Feverish patients on Day-0 (%) 26 (62%) 15 (48%)
Positive Dill Glazko in urine on Day-0 (%) 10 (24%) 8 (26%)
Geometric mean of parasite density on Day-0 (range) 8,758/μL (1,000-62,720) 5,468/μL (1,240 -41,720)
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levels of chloroquine (Day-3) was assessed by comparing
the median of total chloroquine level among failed and
successfully treated subjects. In 33 P. falciparum sub-
jects, chloroquine levels on Day-3 were significantly
higher in successfull than failed subjects (Mann-Whit-
ney: sums rank of success versus failures were 379 vs
182, p value = 0.001) (Figure 1). Nevertheless, in 23 P.
vivax subjects the differences were not significant
(Mann-Whitney: sums rank of success versus failures
were 162 vs 114, p value = 0.245) (see Figure 2). This
smaller sample may lack adequate power to detect such
differences.
28 day test outcomes
Among 42 subjects infected by P. falciparum,3 8w e r e
evaluated based on per protocol analysis. Two were
withdrawn due to mixed infections (Day 14 & 21), and
two subjects did not reappear at the health center after
Day-3 and -21. 16% (6/38) of failures occurred during
peak drug levels (Day-2: 5 subjects; Day-3: 1 subject).
Another nine (24%) failures occurred on Day-7, so that
a total of 40% of treatment failures with P. falciparum
occured within the first week. During Week-2 another
13 subjects (34%) had recurrent parasitaemia, and dur-
ing Week-3 and Week-4 this occurred among three
(8%) and one (3%) subject, respectively. The total pro-
portion of chloroquine treatment failures was 84% (32/
38) among P. falciparum-infected subjects.
Among 31 P. vivax subjects, 23 were evaluated based
on per protocol analysis. Three dropped out (2 on Day-
7 and 1 on Day-21) without citing reasons, and five
withdrew due to intercurrent infection of P. falciparum
(three on Day-21 and two on Day-28). Among subjects
experiencing treament failure, one showed increasing
numbers of parasites on Day-2 (6,640 vs. 7,120 para-
sites/μL) and was classified as a direct treatment failure.
Three subjects showed decreased parasitaemia from
Day-0 to Day-2 or Day-3 (2,680 vs. 280 parasites/μL;
2,200 vs. 360 parasites/μL; & 2,640 vs. 200 parasites/μL).
These three parasitaemias persisted to Day-7 and were
classified as early treament failures. Eleven subjects had
recurrent parasitaemia by Day-14 (4), Day-21 (6) and
Day-28 (1). These were classified as recurrence treat-
ment failures. The crude proportion of chloroquine
treatment failures among P. vivax-infected subjects was
65% (15/23).
Life table analyses
Life table analysis does not censor withdrawn subjects
until the day of loss. In P. falciparum-infected subjects,
10% (6 subjects) failed at peak drug levels on Day-2
&-3, but only four of them (three on Day-2 and one on
Day-3) had chloroquine levels that confirmed resistance.
The other 2 subjects on Day-2 did not have available
blood blots for drug measurement (Table 2). All failures
on Day-7 (9 participants) were resistant, and the 7-day
cumulative incidence of failure was 33%. Furthermore,
on Day-14, 21 & 28 some subjects could not be con-
firmed as resistant (three, one and one subject, respec-
tively) due to CQ+DCQ level being < 200 ng/mL. At
Day-14 the estimated cumulative incidence of therapeu-
t i cf a i l u r ew a s6 1 % .T h i se s t i m a t ew a s6 8 %b yD a y - 2 8
(95% CI: 0.5260 - 0.8306). Among P. vivax-infected sub-
jects, all treatment failures up to Day-14 were confirmed
resistant (8 subjects) (Table 3), and beyond Day-14 four
of seven recurrent parasitaemias were confirmed as
resistant by CQ+DCQ levels >100 ng/mL. The cumula-
tive incidence of confirmed resistance was estimated to
be 3% at Day-3, 13% at Day-7, 27% at Day-14, and 43%
at Day-28 (95% CI: 0.2715 - 0.6384).
Discussion
This small study documented the 28-day cumulative
incidence of chloroquine-resistance in P. falciparum
(68%) and P. vivax (43%) infections acquired in southern
Sumatra in western Indonesia in 2002. In earlier studies
in this region, chloroquine-resistant P. falciparum [2]
and Plasmodium malariae [23] were reported, although
the latter diagnosis has been debated [24]. Nonetheless,
Figure 1 Chloroquine level on Day-3 of P. falciparum subjects.
The median chloroquine level on Day-3 was significantly lower in
failed than succeed groups of P. falciparum subjects (Mann-Whitney
test, p = 0.001). Case number 16 was the outlier of failed subject
with chloroquine level of 703 ng/mL.
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therapy for falciparum malaria throughout Indonesia.
This was finally changed in 2004 to artesunate com-
bined with amodiaquine, although even today only for
confirmed infections. The very high levels of resistance
documented here affirm the necessity of that change in
policy and practice, but these data also serve as a basis
for comparison with the same phenomenon in vivax
malaria, against which chloroquine remains in wide use.
Studies conducted in Indonesia between 1992 and
2001 documented chloroquine-resistant P. vivax (CRPV)
occurring at > 40% risk in Indonesian New Guinea
(Papua, formerly Irian Jaya) [6,8-10]. Similar surveys in
central and western Indonesia, however, revealed rela-
tively low risk (<20%) [3,11-15]. The apparent isolation
of high risk of CRPV to Indonesian New Guinea
encouraged health authorities to maintain chloroquine
as the national first-line therapy for vivax malaria. This
was even true in Papua until 2007 when a location-spe-
cific treatment policy trial was instituted in the area of
Timika, where more recent studies also documented
very high risk of CRPV [10,25]. That first line therapy
for Timika is dihydroartemisinin combined with pipera-
quine, and has been under evaluation by the authorities.
Very recently, in 2008, the Ministry of Health reached
a decision to recommend artesunate-amodiaquine as
first-line therapy against vivax malaria as national treat-
ment policy. This combination therapy is now recom-
mended as first-line treatment for either P. falciparum
or P. vivax across Indonesia. However, many diagnoses
of malaria in Indonesia today are made clinically or
non-specifically, and such cases still receive chloroquine
or sulphadoxine/pyrimethamine therapies. No study has
yet gauged the extent and rate of specific diagnoses and
ACT treatment, and how these practices impact metrics
of malaria risk in any given area.
Figure 2 Chloroquine level on Day-3 of P. vivax subjects. The median chloroquine level on Day-3 was indifferent in failed and succeed
groups of P. vivax subjects (Mann-Whitney test, p = 0.254). Case number 44, 60 & 58 were the outliers of failed subject with chloroquine level of
599, 691 and 827 ng/mL, respectively.
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recently reported trial [19], corroborate the description
of the CRPV situation on the Indonesian archipelago as
worsening. In our other study on Alor Island in the
eastern Lesser Sundas Archipelago, the 28-day risk of
CRPV was estimated at 56%. The current study,
approximately 3,000 km west of Papua, found a 43%
risk of CRPV, well above the prior studies in western
Indonesia ranging from 0% to 20% [3,11-15]. Recent
work from Myanmar [26] also suggests a westward
encroachment of CRPV. With India representing the
nexus of the global vivax malaria burden [27], this trend
merits aggressive surveillance.
Surveillance of CRPV has been hampered by the low
priority assigned to vivax malaria by donors, sponsors
and health agencies. More than two decades after the
e m e r g e n c eo fe v i d e n c eo fas e r i o u sr e s i s t a n c ep r o b l e m ,
the number of surveys of CRPV in that interim any-
where in the world numbers less than a few dozen.
Another inhibiting factor has been the unavailability of
a standardized testing procedure, or the application of
procedures rooted in those for falciparum malaria and
poorly suited for vivax malaria. The analytical methodol-
ogy applied here and in another recent study [19]
derived from earlier work [21], and the terminology
classifying outcomes as sensitive or direct, early or
recurrent treatment failures is our own. These methods
and terminologies are useful and analytically sound in
the narrow context of characterizing resistance to chlor-
oquine by asexual blood stages of P. vivax. The rationale
underpinning these approaches hinge upon pharmacoki-
netics unique to chloroquine and upon the specific sen-
sitivities of P. vivax isolates that may be considered
unambiguously a sensitive phenotype.
In this study, 77% of otherwise eligible subjects with
vivax malaria were excluded on the basis of an arbitrary
minimal parasite count of 1,000/μL. This experience
encouraged us to subsequently abandon such a poten-
tially powerful source of confounding by sample bias.
We acknowledge that such systemic sample bias may in
part explain the apparently high rate of resistance
recorded in this study. A sample that included the med-
ian parasitemia in this community would have very
likely produced a lower cumulative incidence of recur-
rences and more truly represented risk of therapeutic
failure in the study area.
Conclusions
The findings in this study represent only a few dozen
patients from the catchment area of a single health cen-
ter in southern Sumatra, Indonesia. Further surveillance
for CRPV should be carried out in the region to more
reliably characterize risk of CRPV. This is true even
though chloroquine is no longer first-line therapy for
vivax malaria in Indonesia. Some years may pass before
existing stocks of chloroquine become exhausted and
the drug is likely to see fairly extensive use, including
through private marketers catering to a brisk over-the-
counter trade in this drug.
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